TLR7 AGONIST AND COMBINATIONS FOR CANCER TREATMENT
The present disclosure relates to the specific TLR7 agonist BNT411, such as compositions and kits comprising BNT411, and the use of BNT411 as immunotherapeutic agent in monotherapy and combination therapy to reduce or prevent progression of a tumor, in particular a solid tumor, or treating cancer, i...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | RÖSEMANN, Roman HASSAN, Hariz Iskandar Bin SAHIN, Ugur STROBL, Stefan |
| description | The present disclosure relates to the specific TLR7 agonist BNT411, such as compositions and kits comprising BNT411, and the use of BNT411 as immunotherapeutic agent in monotherapy and combination therapy to reduce or prevent progression of a tumor, in particular a solid tumor, or treating cancer, in particular a solid cancer.
La présente invention concerne l'agoniste de TLR7 spécifique BNT411, ainsi que des compositions et des kits comprenant BNT411, et l'utilisation de BNT411 en tant qu'agent immunothérapeutique en monothérapie et polythérapie pour réduire ou prévenir la progression d'une tumeur, en particulier d'une tumeur solide, ou traiter le cancer, en particulier un cancer solide. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2023083868A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2023083868A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2023083868A13</originalsourceid><addsrcrecordid>eNrjZDAK8QkyV3B09_fzDA5RcPRzUXD293Xy9HMM8fT3C1Zw8w9ScHb0c3YNUggJcnUM8XX1C-FhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfHh_kYGRsYGFsYWZhaOhsbEqQIABxwntw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>TLR7 AGONIST AND COMBINATIONS FOR CANCER TREATMENT</title><source>esp@cenet</source><creator>RÖSEMANN, Roman ; HASSAN, Hariz Iskandar Bin ; SAHIN, Ugur ; STROBL, Stefan</creator><creatorcontrib>RÖSEMANN, Roman ; HASSAN, Hariz Iskandar Bin ; SAHIN, Ugur ; STROBL, Stefan</creatorcontrib><description>The present disclosure relates to the specific TLR7 agonist BNT411, such as compositions and kits comprising BNT411, and the use of BNT411 as immunotherapeutic agent in monotherapy and combination therapy to reduce or prevent progression of a tumor, in particular a solid tumor, or treating cancer, in particular a solid cancer.
La présente invention concerne l'agoniste de TLR7 spécifique BNT411, ainsi que des compositions et des kits comprenant BNT411, et l'utilisation de BNT411 en tant qu'agent immunothérapeutique en monothérapie et polythérapie pour réduire ou prévenir la progression d'une tumeur, en particulier d'une tumeur solide, ou traiter le cancer, en particulier un cancer solide.</description><language>eng ; fre</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230519&DB=EPODOC&CC=WO&NR=2023083868A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230519&DB=EPODOC&CC=WO&NR=2023083868A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>RÖSEMANN, Roman</creatorcontrib><creatorcontrib>HASSAN, Hariz Iskandar Bin</creatorcontrib><creatorcontrib>SAHIN, Ugur</creatorcontrib><creatorcontrib>STROBL, Stefan</creatorcontrib><title>TLR7 AGONIST AND COMBINATIONS FOR CANCER TREATMENT</title><description>The present disclosure relates to the specific TLR7 agonist BNT411, such as compositions and kits comprising BNT411, and the use of BNT411 as immunotherapeutic agent in monotherapy and combination therapy to reduce or prevent progression of a tumor, in particular a solid tumor, or treating cancer, in particular a solid cancer.
La présente invention concerne l'agoniste de TLR7 spécifique BNT411, ainsi que des compositions et des kits comprenant BNT411, et l'utilisation de BNT411 en tant qu'agent immunothérapeutique en monothérapie et polythérapie pour réduire ou prévenir la progression d'une tumeur, en particulier d'une tumeur solide, ou traiter le cancer, en particulier un cancer solide.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDAK8QkyV3B09_fzDA5RcPRzUXD293Xy9HMM8fT3C1Zw8w9ScHb0c3YNUggJcnUM8XX1C-FhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfHh_kYGRsYGFsYWZhaOhsbEqQIABxwntw</recordid><startdate>20230519</startdate><enddate>20230519</enddate><creator>RÖSEMANN, Roman</creator><creator>HASSAN, Hariz Iskandar Bin</creator><creator>SAHIN, Ugur</creator><creator>STROBL, Stefan</creator><scope>EVB</scope></search><sort><creationdate>20230519</creationdate><title>TLR7 AGONIST AND COMBINATIONS FOR CANCER TREATMENT</title><author>RÖSEMANN, Roman ; HASSAN, Hariz Iskandar Bin ; SAHIN, Ugur ; STROBL, Stefan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2023083868A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2023</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>RÖSEMANN, Roman</creatorcontrib><creatorcontrib>HASSAN, Hariz Iskandar Bin</creatorcontrib><creatorcontrib>SAHIN, Ugur</creatorcontrib><creatorcontrib>STROBL, Stefan</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>RÖSEMANN, Roman</au><au>HASSAN, Hariz Iskandar Bin</au><au>SAHIN, Ugur</au><au>STROBL, Stefan</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>TLR7 AGONIST AND COMBINATIONS FOR CANCER TREATMENT</title><date>2023-05-19</date><risdate>2023</risdate><abstract>The present disclosure relates to the specific TLR7 agonist BNT411, such as compositions and kits comprising BNT411, and the use of BNT411 as immunotherapeutic agent in monotherapy and combination therapy to reduce or prevent progression of a tumor, in particular a solid tumor, or treating cancer, in particular a solid cancer.
La présente invention concerne l'agoniste de TLR7 spécifique BNT411, ainsi que des compositions et des kits comprenant BNT411, et l'utilisation de BNT411 en tant qu'agent immunothérapeutique en monothérapie et polythérapie pour réduire ou prévenir la progression d'une tumeur, en particulier d'une tumeur solide, ou traiter le cancer, en particulier un cancer solide.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2023083868A1 |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | TLR7 AGONIST AND COMBINATIONS FOR CANCER TREATMENT |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T13%3A13%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=R%C3%96SEMANN,%20Roman&rft.date=2023-05-19&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2023083868A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |